Objective To evaluate the efficacy of apalutamide combined with androgen deprivation therapy(ADT)in the treatment of metastatic hormone-sensitive prostate cancer(mHSPC).Methods The clinical data of 53 mHSPCpatients received apalutamide combined with ADT treatment were retrospectively analyzed.The response rate of prostate specific antigen(PSA),changes in maximum tumor diameter and occurrence of adverse drug reactions after treatment were evaluated after follow-up for 6 months.Results Compared to the initial PSA before treatment,after 6 months of treatment,serum PSA levels of all patients were decreased by more than 50％,and serum PSA levels of 51(96.23％)patients were decreased by more than 90％.Fourteen patients were followed up with prostate enhanced MRI,the maximum tumor diameter of the lesion was decreased after treatment compared to that before treatment[(23.87±10.58)mm vs.(47.00±21.93)mm](P＜0.05).Of 53 patients,8(15.09％)cases experienced varying degrees of rash,and 11(20.75％)cases experienced fatigue and decreased appetite.Conclusion Apalutamide combined with ADT treatment has a good PSA response rate and safety in the patients with mHSPC,which can effectively reduce the tumor diameter.
ApalutamideAndrogen deprivation therapyMetastatic hormone-sensitive prostate cancerProstate specific antigen
NETL
NSTL
万方数据
